Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma Interventions: Drug: Lenvatinib; Drug: Placebo; Drug: Immunosuppressive regimen Sponsor: RenJi Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Hospitals | Liver | Liver Cancer | Liver Transplant | Research | Transplants | Urology & Nephrology